Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 3/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | HTR2B | P41595 | 2/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.52 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.52 |
| ▸ | NAE1 | Q13564 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8265591 | 0.89 | AGTR1 (0.64) | AGTR2AGTR1CYP3A4ADORA3ADRA2B | |
| SCHEMBL22533557 | 0.88 | AGTR2 (0.51) | AGTR2AGTR1CYP3A4ADORA3ADRA2B | |
| SCHEMBL3977106 | 0.88 | AGTR2 (0.62) | AGTR2AGTR1CYP3A4ADORA3ADRA2B | |
| SCHEMBL4620376 | 0.84 | KMT2A (0.40) | AGTR2AGTR1CYP3A4ADORA3ADRA2B | |
| SCHEMBL7018017 | 0.84 | PPARG (0.59) | AGTR2AGTR1CYP3A4ADORA3ADRA2B | |
| SCHEMBL21168140 | 0.84 | AGTR2 (0.59) | AGTR2AGTR1CYP3A4ADORA3ADRA2B | |
| SCHEMBL30206864 | 0.84 | PPARG (0.59) | AGTR2AGTR1CYP3A4ADORA3ADRA2B | |
| SCHEMBL12476143 | 0.84 | AGTR2 (0.58) | AGTR2AGTR1CYP3A4ADORA3ADRA2B | |
| SCHEMBL21083997 | 0.83 | NAE1 (0.55) | AGTR2AGTR1CYP3A4ADORA3ADRA2B | |
| SCHEMBL21167865 | 0.83 | AGTR2 (0.57) | AGTR2AGTR1CYP3A4ADORA3ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3478672-B1 | BIARYLMETHYL HETEROCYCLES | UNIV MONTREAL (CA) | 2024-04-10 | — | — | EP | disclosed |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | Université de Montréal (CA) | 2023-02-09 | — | — | US | disclosed |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | Université de Montréal (CA) | 2023-02-09 | — | — | US | disclosed |
| US-11407733-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-08-09 | — | — | US | disclosed |
| US-20190202808-A1 | BIARYLMETHYL HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-04 | — | — | US | disclosed |
| US-20190202808-A1 | BIARYLMETHYL HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-04 | — | — | US | disclosed |
| US-10300471-B2 | Ruthenium-catalyzed synthesis of biaryl compounds in water | CHICAGO DISCOVERY SOLUTIONS, LLC | 2019-05-28 | — | — | US | disclosed |
| US-20160263565-A1 | RUTHENIUM-CATALYZED SYNTHESIS OF BIARYL COMPOUNDS IN WATER | CHICAGO DISCOVERY SOLUTIONS, LLC (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015054120-A1 | RUTHENIUM-CATALYZED SYNTHESIS OF BIARYL COMPOUNDS IN WATER | CHICAGO DISCOVERY SOLUTIONS, LLC (US) | 2015-04-16 | — | — | WO | disclosed |
| EP-1838699-B1 | METHOD FOR PRODUCTION OF CANDESARTAN | RATIOPHARM GMBH (DE) | 2010-04-28 | — | — | EP | disclosed |
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| EP-1996588-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | Torrent Pharmaceuticals Ltd (IN) | 2008-12-03 | — | — | EP | disclosed |
| US-20080114045-A1 | Process for the Production of Candesartan | GRAF-ARCO-STR. 3 (DE) | 2008-05-15 | — | — | US | disclosed |
| US-20080114045-A1 | Process for the Production of Candesartan | GRAF-ARCO-STR. 3 (DE) | 2008-05-15 | — | — | US | disclosed |
| WO-2007100295-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | TORRENT PHARMACEUTICALS LTD (IN) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407733-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | AGTR2 6/4885AGTR1 7/4885CYP3A4 573/4885 |
| US-20190202808-A1 | BIARYLMETHYL HETEROCYCLES | ARRB1, ADRB2, ADRB1 | AGTR2 6/4885AGTR1 7/4885CYP3A4 573/4885 |
| US-10300471-B2 | Ruthenium-catalyzed synthesis of biaryl compounds in water | RUVBL2, RUVBL1, CYP2W1 | AGTR2 265/4885AGTR1 372/4885CYP3A4 77/4885 |
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | EDNRA, EDNRB, AGTR1 | AGTR2 4/4885AGTR1 3/4885CYP3A4 2927/4885 |
| US-20080114045-A1 | Process for the Production of Candesartan | REN, AGTR1, ACE | AGTR2 5/4885AGTR1 2/4885CYP3A4 157/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | AGTR2 6/4885AGTR1 7/4885CYP3A4 573/4885 |
| US-20160263565-A1 | RUTHENIUM-CATALYZED SYNTHESIS OF BIARYL COMPOUNDS IN WATER | RUVBL2, RUVBL1, CYP2W1 | AGTR2 265/4885AGTR1 372/4885CYP3A4 77/4885 |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | ARRB1, ADRB2, ADRB1 | AGTR2 6/4885AGTR1 7/4885CYP3A4 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.